|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. |
| 公司地址
| 555 Long Wharf Drive, New Haven, CT, USA, 06511 |
| 電話號碼
| +1 475 238-6837 |
| 傳真號碼
| +1 475 238-6837 |
| 公司網頁
| https://www.bioxceltherapeutics.com |
| 員工數量
| 29 |
| Mr. Richard I. Steinhart |
Senior Vice President, Chief Financial Officer and Principal Accounting Officer |
美元 409.87K |
27/03/2026 |
| Dr. Vimal Mehta, PhD |
Director, Chief Executive Officer and President |
美元 1.00M |
27/03/2026 |
| Dr. Frank D. Yocca, PhD |
Senior Vice President and Chief Scientific Officer |
-- |
27/03/2026 |
| Mr. Javier Rodriguez |
Senior Vice President, Chief Legal Officer and Corporate Secretary |
美元 423.83K |
27/03/2026 |
|
|
| Mr. Michael Miller |
Independent Director |
27/03/2026 |
| Dr. Peter Mueller,PhD |
Chairman of the Board |
27/03/2026 |
| Dr. Michal Votruba, M.D.,PhD |
Independent Director |
27/03/2026 |
| Dr. Sandeep Laumas, M.D. |
Independent Director |
27/03/2026 |
| Dr. Vimal Mehta, PhD |
Director, Chief Executive Officer and President |
27/03/2026 |
| Ms. June Bray |
Independent Director |
27/03/2026 |
| Mr. David J. Mack |
Independent Director |
27/03/2026 |
| Dr. Rajiv Patni, M.D. |
Director |
27/03/2026 |
|
|
|
|
